{"id":"bevazizumab-intravitreal-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain or discomfort"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Endophthalmitis"},{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Cataract progression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to and neutralizes VEGF, a key signaling molecule that promotes pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF, the drug reduces abnormal blood vessel growth and leakage, stabilizing or improving vision in conditions characterized by retinal neovascularization and macular edema. When administered as an intravitreal injection, it delivers the therapeutic agent directly to the posterior segment of the eye.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:12.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular age-related macular degeneration (wet AMD)"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion with macular edema"},{"name":"Proliferative diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT01716026","phase":"PHASE3","title":"Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2012-10","conditions":"Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia","enrollment":66},{"nctId":"NCT00557232","phase":"PHASE4","title":"Intraocular Bevacizumab (Avastin) for Rubeosis Iridis","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2006-11","conditions":"Glaucoma, Rubeosis Iridis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin Injection"],"phase":"phase_3","status":"active","brandName":"Bevazizumab intravitreal injection","genericName":"Bevazizumab intravitreal injection","companyName":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","companyId":"instituto-universitario-de-oftalmobiolog-a-aplicada-institute-of-applied-ophthal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye. Used for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema, Retinal vein occlusion with macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}